Swiss Pharm Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SWISS PHARM, and what generic and branded alternatives to SWISS PHARM drugs are available?
SWISS PHARM has three approved drugs.
Summary for Swiss Pharm
US Patents: | 0 |
Tradenames: | 3 |
Ingredients: | 3 |
NDAs: | 3 |
PTAB Cases with Swiss Pharm as petitioner: | See PTAB cases with Swiss Pharm as petitioner |
Drugs and US Patents for Swiss Pharm
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Swiss Pharm | NIFEDIPINE | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 216019-001 | Nov 18, 2022 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Swiss Pharm | ENTECAVIR | entecavir | TABLET;ORAL | 212106-001 | Aug 10, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Swiss Pharm | VENLAFAXINE HYDROCHLORIDE | venlafaxine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 214423-001 | Jan 4, 2022 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Swiss Pharm | VENLAFAXINE HYDROCHLORIDE | venlafaxine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 214423-002 | Jan 4, 2022 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Swiss Pharm | ENTECAVIR | entecavir | TABLET;ORAL | 212106-002 | Aug 10, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Swiss Pharm | NIFEDIPINE | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 216019-002 | Nov 18, 2022 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.